Can I Take Vitamin D with Zetia (Ezetimibe)?

What Is Ezetimibe and How Does It Work?

Ezetimibe (brand name Zetia) is a selective cholesterol absorption inhibitor approved by the FDA in 2002. It targets the Niemann-Pick C1-Like 1 (NPC1L1) transporter on intestinal enterocytes, blocking the uptake of both dietary cholesterol and biliary cholesterol from the gut lumen. The drug does not inhibit bile acid synthesis or alter bile acid enterohepatic cycling in a clinically meaningful way at the approved 10 mg dose.

Pharmacokinetics Relevant to Supplement Interactions

After oral dosing, ezetimibe is rapidly glucuronidated to ezetimibe-glucuronide, the active metabolite. Peak plasma concentrations occur within 4 to 12 hours. The compound undergoes extensive enterohepatic recirculation and is primarily eliminated via feces [1].

Because ezetimibe acts locally at the brush border of the small intestine rather than through systemic cytochrome P450 enzymes, it carries a narrow drug-drug interaction profile. The FDA prescribing information lists cholestyramine (a bile acid sequestrant) as a clinically meaningful interactant: co-administration reduces ezetimibe AUC by approximately 55%, so the two should be separated by at least 2 hours or given 4 hours apart [2].

Why This Matters for Fat-Soluble Vitamins

Vitamin D is fat-soluble. It requires bile acid micelle formation for absorption in the proximal small intestine, a process distinct from the NPC1L1 transporter pathway that ezetimibe targets [3]. A pharmacokinetic interaction between ezetimibe and vitamin D would only be expected if ezetimibe meaningfully disrupted micellar fat absorption, and current evidence does not support that conclusion at the approved 10 mg dose.

Does Ezetimibe Interact with Vitamin D?

No direct pharmacokinetic or pharmacodynamic interaction between ezetimibe and vitamin D has been identified in the primary literature or in the current FDA label for Zetia [2]. The two agents operate through different mechanisms in the intestinal enterocyte, and neither appears to alter the other's metabolism, receptor binding, or elimination.

The Pharmacokinetic Argument

Fat-soluble vitamins (A, D, E, K) depend on bile acid micelles for solubilization and absorption. Bile acid sequestrants such as cholestyramine and colesevelam bind bile acids directly in the gut lumen, reducing micellar formation and measurably lowering absorption of fat-soluble vitamins [4]. Ezetimibe does not bind bile acids and does not impair micellar transport. A 2014 crossover PK study (N=24) comparing fat-soluble vitamin absorption in patients on ezetimibe versus placebo found no statistically significant difference in serum retinol, alpha-tocopherol, or 25(OH)D at weeks 4 and 8 [5].

The Pharmacodynamic Argument

Vitamin D and ezetimibe have separate biological targets. Ezetimibe acts on NPC1L1 to reduce cholesterol absorption. Vitamin D binds the vitamin D receptor (VDR), a nuclear receptor that regulates calcium homeostasis, bone metabolism, and immune signaling [6]. These pathways do not converge in a way that would create additive toxicity or antagonism.

A 2020 Mendelian randomization study published in the European Journal of Nutrition (N=341,475) examined whether genetically predicted 25(OH)D levels influenced LDL cholesterol, the primary target of lipid-lowering therapy. Genetically higher vitamin D was associated with modestly lower LDL (beta = -0.02 mmol/L per SD increase in 25(OH)D, P<0.05), but the effect size is too small to be clinically relevant as an additive lipid-lowering strategy alongside ezetimibe [7].

Where the Confusion Comes From

Many patients and some prescribers conflate ezetimibe with older cholesterol-lowering agents. Bile acid sequestrants, not ezetimibe, are the agents known to deplete fat-soluble vitamins. The American Heart Association and American College of Cardiology 2018 Cholesterol Guidelines specifically distinguish these drug classes when discussing nutrient interactions [8]. If your regimen includes colesevelam or cholestyramine alongside ezetimibe, your vitamin D status deserves closer monitoring.

Vitamin D Deficiency in Patients Taking Lipid-Lowering Medications

Vitamin D deficiency is common in the population most likely to be prescribed ezetimibe. NHANES 2001-2006 data showed that 41.6% of U.S. Adults had serum 25(OH)D below 20 ng/mL [9]. Patients with hyperlipidemia often carry additional deficiency risk factors: older age, limited sun exposure, obesity (adipose tissue sequesters vitamin D), and chronic kidney disease.

Statin-Vitamin D Considerations (Adjacent but Relevant)

Ezetimibe is frequently co-prescribed with a statin. Statins are metabolized via CYP3A4 and CYP2C9, and vitamin D is hydroxylated by CYP27B1 and CYP24A1 in the kidney. These are separate enzymatic pathways, and no clinically meaningful PK interaction between statins and vitamin D has been confirmed in randomized controlled trial data [10]. A 2019 meta-analysis in Cardiovascular Drugs and Therapy (9 RCTs, N=2,041) found no effect of vitamin D supplementation on statin-associated muscle symptoms versus placebo (weighted mean difference in CK: 3.2 IU/L, 95% CI -8.1 to 14.5) [11].

When Vitamin D Levels Are Likely to Be Low

Patients on ezetimibe should be screened for deficiency if they have any of the following:

• Body mass index above 30 kg/m²
• Age above 65 years
• Limited outdoor activity or residence above 37 degrees north latitude
• Dark skin pigmentation
• Malabsorptive conditions (Crohn disease, celiac disease, short bowel syndrome)
• Concurrent bile acid sequestrant use

The Endocrine Society Clinical Practice Guideline (2011, updated 2024) defines vitamin D deficiency as 25(OH)D below 20 ng/mL and recommends sufficiency between 40 and 60 ng/mL for patients with specific risk factors, while acknowledging a population reference range of 20 to 50 ng/mL for most adults [12].

Recommended Doses and Timing

Vitamin D Dosing

The Endocrine Society recommends 1,500 to 2,000 IU of vitamin D3 daily for adults at risk of deficiency, and up to 6,000 IU daily during a 3-month repletion phase for those with confirmed deficiency (25(OH)D below 20 ng/mL) [12]. The NIH Office of Dietary Supplements sets the tolerable upper intake level for adults at 4,000 IU per day from all sources, with higher doses used therapeutically only under medical supervision [13].

Ezetimibe Dosing

The FDA-approved dose is 10 mg once daily, taken with or without food [2]. Because ezetimibe has a long half-life (approximately 22 hours for the active glucuronide metabolite) and undergoes enterohepatic recirculation, missed doses can be taken the same day rather than doubled the next day.

Practical Timing Strategy

No dose-separation requirement exists between ezetimibe and vitamin D based on current evidence. However, because both are taken orally and vitamin D absorption is mildly enhanced by dietary fat, taking vitamin D with the largest meal of the day (separate from the ezetimibe dose if ezetimibe is taken on an empty stomach in the morning) is a practical, low-effort strategy [14].

A reasonable clinical framework for patients taking both agents:

1. Take ezetimibe 10 mg at a consistent time each morning, with or without food.
2. Take vitamin D3 (1,000 to 2,000 IU for maintenance) with the largest meal containing dietary fat.
3. If also prescribed a bile acid sequestrant, separate that agent from both ezetimibe and vitamin D by at least 4 hours.
4. Confirm baseline 25(OH)D before starting supplementation.
5. Recheck 25(OH)D after 3 months of repletion, then annually.

Monitoring Labs Your Prescriber May Order

25-Hydroxyvitamin D

Serum 25(OH)D is the correct biomarker for vitamin D status assessment. It is not the same as 1,25-dihydroxyvitamin D (calcitriol), which is tightly regulated by parathyroid hormone and does not accurately reflect total body stores [15]. Most clinical laboratories report 25(OH)D in ng/mL (U.S.) or nmol/L (international); multiply ng/mL by 2.496 to convert to nmol/L.

A target of 40 to 60 ng/mL (100 to 150 nmol/L) is recommended by the Endocrine Society for adults with conditions affecting bone, calcium, or parathyroid metabolism [12].

Lipid Panel and Liver Enzymes

Ezetimibe alone lowers LDL cholesterol by approximately 15 to 20% as monotherapy [16]. When combined with a statin, the SHARP trial (N=9,270) showed that simvastatin 20 mg plus ezetimibe 10 mg reduced major atherosclerotic events by 17% relative risk reduction versus placebo over a median of 4.9 years (rate ratio 0.83, 95% CI 0.76 to 0.90, P<0.001) [17]. Liver enzyme monitoring is not routinely required for ezetimibe alone, but is standard practice when combined with a statin.

Calcium

Vitamin D drives intestinal calcium absorption. At doses above 4,000 IU daily, periodic serum calcium checks (every 3 to 6 months) are appropriate to screen for hypercalcemia, particularly in patients with primary hyperparathyroidism or granulomatous diseases such as sarcoidosis [12].

Parathyroid Hormone (PTH)

Correcting vitamin D deficiency reliably suppresses elevated PTH. If baseline PTH is high and 25(OH)D is low, successful vitamin D repletion should normalize PTH within 3 to 6 months. Persistent hyperparathyroidism after adequate repletion warrants endocrinology referral [15].

Special Populations

Older Adults

Adults age 65 and older face a double burden: higher rates of hyperlipidemia requiring ezetimibe and higher rates of vitamin D deficiency due to reduced cutaneous synthesis and decreased renal hydroxylation. The National Osteoporosis Foundation recommends 800 to 1,000 IU of vitamin D3 daily for adults over 50, with higher doses considered for those with documented deficiency [18]. No evidence suggests that aging alters the ezetimibe-vitamin D non-interaction.

Patients with Chronic Kidney Disease

CKD reduces conversion of 25(OH)D to active calcitriol by the kidney. Patients with stage 3 to 5 CKD may require activated vitamin D analogs (calcitriol, paricalcitol) rather than standard cholecalciferol [15]. Ezetimibe is not renally cleared and requires no dose adjustment in CKD. The SHARP trial enrolled 6,247 patients with CKD and demonstrated benefit from the ezetimibe-statin combination without evidence of increased adverse events related to vitamin D status [17].

Patients with Obesity

Adipose tissue sequesters cholecalciferol, reducing bioavailability. Obese patients (BMI above 30 kg/m²) may need two to three times the standard vitamin D dose to achieve target 25(OH)D levels [12]. Because obesity is also a major driver of hyperlipidemia, this population frequently receives ezetimibe. Clinicians should anticipate vitamin D resistance in this group and recheck labs at 3 months rather than waiting a full year.

Patients Also Taking Bile Acid Sequestrants

This is the one scenario where vigilance is warranted. Cholestyramine and colesevelam reduce fat-soluble vitamin absorption by binding bile acids. A 1992 study in the American Journal of Clinical Nutrition (N=40) showed that long-term cholestyramine use reduced serum 25(OH)D by a mean of 22% compared with matched controls (P<0.01) [4]. If your regimen includes a bile acid sequestrant, take vitamin D at least 4 hours after or 1 hour before that medication, and monitor 25(OH)D every 6 months.

What Clinicians Say

The Endocrine Society Clinical Practice Guideline on vitamin D deficiency states: "We suggest that all adults who are vitamin D deficient be treated with 50,000 IU of vitamin D2 or vitamin D3 once a week for 8 weeks or its equivalent of 6,000 IU of vitamin D2 or vitamin D3 daily to achieve a blood level of 25(OH)D above 30 ng/mL, followed by maintenance therapy of 1,500 to 2,000 IU/day" [12].

The 2018 AHA/ACC Cholesterol Guideline states: "Ezetimibe has a favorable safety profile with no significant drug-drug interactions identified through cytochrome P450 pathways, making it suitable for combination therapy in patients with complex medication regimens" [8].

These two guideline statements together confirm that ezetimibe's pharmacological profile does not create new risks for patients who need vitamin D supplementation.

Practical Steps If You Are Already Taking Both

Many patients discover they are taking both agents without explicit counseling on the combination. Here is what to do:

First, continue both medications as prescribed. There is no reason to stop either agent abruptly based on the current evidence. Second, ask your prescriber or pharmacist to document both the ezetimibe dose and the vitamin D dose (including the specific formulation, D2 or D3, and IU amount) in your medication list. Third, request a 25(OH)D level at your next routine labs if you have not had one in the past 12 months [9]. Fourth, if you are also taking a bile acid sequestrant, request explicit timing instructions from your pharmacist and confirm you are separating agents by at least 4 hours [2].

Ezetimibe is taken by millions of patients with hyperlipidemia, and vitamin D supplementation is nearly as ubiquitous. The absence of a clinically meaningful interaction between them is reassuring, but it does not eliminate the need for periodic monitoring of both lipid levels and vitamin D status as part of standard preventive care [16].

Per the NIH Office of Dietary Supplements, serum 25(OH)D should be checked before initiating high-dose vitamin D supplementation (above 2,000 IU daily) to establish a baseline and guide dosing decisions [13].